Anxiety News and Research

Latest Anxiety News and Research

Work is causing stress for more Seattleites, reveals APA survey

Work is causing stress for more Seattleites this year according to the American Psychological Association's (APA) Stress in America survey, while the number reporting money or the economy as significant stressors has dropped since last year. More than 50 percent of city residents remain stressed by one or more of these three sources, a cause of concern for psychologists who worry about the effects of long-term stress and how it can contribute to chronic health disorders.

4 Nov 2009

Work, money and job stability are significant sources of stress for Denver residents

More Denver residents say that their work, money and job stability are significant sources of stress than Americans nationwide, according to the American Psychological Association's (APA) Stress in America survey.

4 Nov 2009

Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease

Pfizer Inc and Medivation, Inc. today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer’s disease (AD).

4 Nov 2009

More Atlanta residents are stressed about the economy according to APA survey

More Atlanta residents are stressed about the economy this year according to the American Psychological Association's (APA) Stress in America survey, while the number of Atlantans reporting money or work as significant stressors in 2009 has dropped. More than 60 percent of city residents continue to report that money, work and the economy are significant sources of stress -- a cause of concern for psychologists who worry about the effects of long-term stress and how it can contribute to chronic health disorders.

4 Nov 2009

NIH awards $4 million research grant to AllTranz

AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company’s transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.

3 Nov 2009

Individuals who had experienced trauma exposure in both childhood and adulthood likely to develop PTSD

Individuals who experience both childhood adversity and traumatic events in adulthood appear more likely to develop post-traumatic stress disorder than those exposed to only one of these types of incidents, according to a report in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals. In addition, the risk was further increased in individuals with a certain genetic mutation.

3 Nov 2009

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Seaside Therapeutics LLC today announced that the Company has initiated a Phase 1 clinical trial of STX107, a highly potent, selective mGluR5 antagonist, in development for the treatment of Fragile X Syndrome. The single ascending dose study is designed to evaluate the safety, tolerability and pharmacokinetics of STX107 in healthy volunteers. Fragile X Syndrome is the most common inherited form of mental impairment and the most common known cause of autism.

3 Nov 2009

Sexual relationships were significantly affected after a stroke, says study

Dr Assumpta Ryan and Hilary Thompson recently published findings from a study involving 16 married stroke survivors - nine males and seven females - aged between 33 and 78.

3 Nov 2009

Phase 1 study of STX107 for Fragile X syndrome begins

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.

3 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

NUVIGIL improves wakefulness in patients with excessive sleepiness associated with shift work disorder

Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD).

3 Nov 2009

High prevalence of nocturnal teeth grinding in patients with OSA

There is a high prevalence of nocturnal teeth grinding, or bruxism, in patients with obstructive sleep apnea (OSA), particularly in Caucasians. New research presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that nearly 1 in 4 patients with OSA suffers from nighttime teeth grinding; this seems to be especially more prevalent in men and in Caucasians compared with other ethnic groups.

3 Nov 2009

AST develops two new holiday season tip sheets for families of children with autism

Autism Spectrum Therapies (AST), an agency providing behavior therapy and other autism services throughout Southern California, has developed two new holiday season tip sheets especially for families of children with autism: Stress-Free Holidays and Top Toy Recommendations.

3 Nov 2009

A look at faculty health

On average, research shows, the United States loses the equivalent of at least one entire medical school class each year to suicide1 - as many as 400 physicians. The book Faculty Health in Academic Medicine: Scientists, Physicians, and the Pressures of Success (Humana Press/Springer), by faculty at The University of Texas M. D. Anderson Cancer Center and other national medical experts, breaks new ground in a first-of-its-kind look at faculty health.

2 Nov 2009

Deep brain stimulation can help patients with severe forms of depression

In deep brain stimulation, doctors specifically target the impaired function of certain areas of the brain with an electric brain pacemaker. For the purpose of this study, they implanted electrodes in what is known as the nucleus accumbens. That is an important part of the 'reward system' which ensures that we remember good experiences and puts us in a state of pleasant anticipation.

2 Nov 2009

American Diabetes Association launches "Stop Diabetes" campaign

Americans earn a failing grade on diabetes awareness, based on survey results released today by the American Diabetes Association. In general, Americans earned a 51% when asked a series of questions about a disease so common that it strikes every 20 seconds. The survey results revealed that many diabetes myths and misconceptions still exist, while the disease's prevalence continues to rise.

2 Nov 2009

Shire to present key data on ADHD treatments at national psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

31 Oct 2009

Shire announces Phase IIIb study results of Daytrana

Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

31 Oct 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Stress-evoked changes can precipitate low mood and re-ignite drug-seeking behaviors

Stress-evoked changes in circuits that regulate serotonin in certain parts of the brain can precipitate a low mood and a relapse in cocaine-seeking, based on mouse studies published online this week in the Proceedings of the National Academy of Sciences.

31 Oct 2009